ASH 2018 | Investigating ibrutinib for CLL: IciCLLe & CLARITY

Peter Hillmen

Peter Hillmen, MBChB, FRCP, FRCPath, PhD, of the University of Leeds, Leeds, UK, discusses the results of Bloodwise’s Trials Acceleration Programme (TAP) IciCLLe (ISRCTN12695354) and CLARITY (ISCRTN13751862) studies, investigating the safety and efficacy of ibrutinib for patients with chronic lymphocytic leukemia (CLL). Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Prof. Hillmen describes the high response rates, MRD results and toxicity profile of ibrutinib in a range of settings.

Share this video